Impact of timing of PERT on gastrointestinal symptoms in Danish children and adolescents with CF-Reference-Cited by-同舟云学术

Impact of timing of PERT on gastrointestinal symptoms in Danish children and adolescents with CF

Published:2021-10-28 Issue:2 Volume:111 Page:432-439
ISSN:0803-5253
Container-title:Acta Paediatrica
language:en
Short-container-title:Acta Paediatrica

Author:

Raun Anne Mette Terp¹²,Brekke Ghita¹²^ORCID,Mølgaard Christian¹³,Jaudszus Anke⁴,Mainz Jochen G.⁵⁶,Pressler Tacjana²,Skov Marianne²

Affiliation:

1. Rigshospitalet, Pediatric Nutrition Unit Copenhagen University HospitalRigshospitalet Copenhagen Denmark

2. Rigshospitalet, CF Center CopenhagenDepartment of Pediatrics and Adolescent Medicine Copenhagen Denmark

3. Department of Nutrition, Exercise and Sports University of Copenhagen Copenhagen Denmark

4. Jena University Hospital Jena Thüringen Germany

5. Cystic Fibrosis Center Brandenburg Medical School (MHB) University Brandenburg an der Havel Germany

6. Faculty of Health Sciences Joint Faculty of the Brandenburg University of Technology Cottbus –Senftenberg The Brandenburg Medical School Theodor FontaneUniversity of Potsdam, Cottbus Brandenburg an der Havel and Potsdam Germany

Publisher

Wiley

Subject

General Medicine,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apa.16143

Reference27 articles.

1. Cystic fibrosis

2. ZolinA OrentiA NaehrlichL et al. ECFSPR Annual Report. 2020;2018:1‐173.

3. Assessing Exocrine Pancreatic Function

4. Approach to chronic abdominal pain in Cystic Fibrosis

5. Relation of Ultrasound Findings and Abdominal Symptoms obtained with the CFAbd-Score in Cystic Fibrosis Patients

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis;Clinical Nutrition;2024-02

2. Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire;Frontiers in Pharmacology;2023-10-25

3. Dynamics of abdominal symptoms during the start of a new therapy with Elexacaftor/Tezacaftor/Ivacaftor using the novel CFAbd-day2day questionnaire;2023-08-02

4. Thinking outside the box: a review of gastrointestinal symptoms and complications in cystic fibrosis;Expert Review of Respiratory Medicine;2023-06-26

5. Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score;Frontiers in Pharmacology;2022-06-03